Vontobel Holding
KPTI icon

Vontobel Holding’s Karyopharm Therapeutics KPTI Stock Holding History

Vontobel Holding’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$175K – 1153
2021
Q3 		$175K Hold
2,000
– – ﹤0.01% 1049
2021
Q2 		$310K Hold
2,000
– – ﹤0.01% 907
2021
Q1 		$316K Buy
2,000
+435
+28% +$91.7K ﹤0.01% 785
2020
Q4 		$363K Buy
+1,565
New +$363K ﹤0.01% 753

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Vontobel Holding's KPTI Position: Q4 2021 in Review

Vontobel Holding sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 2,000 shares — an estimated $175K sold.

Vontobel Holding first reported a position in KPTI in Q4 2020 and held it in 4 quarters. The position peaked at $363K in Q4 2020. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

  • Vontobel Holding reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Vontobel Holding sold 2,000 Karyopharm Therapeutics shares in Q4 2021, an estimated $175K.
  • Vontobel Holding first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 4 quarters.
  • Vontobel Holding's Karyopharm Therapeutics position peaked at $363K in Q4 2020.
  • 143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Vontobel Holding's 13F filing for Q4 2021, filed 10 Feb 2022.